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N ick Hastie was born in thevillage of Rhos-on-Sea, NorthWales, and as a child neveronce imagined becoming a scientist. Although he claims
that social acumen and a good mentor helped
get his career off the ground initially, as an 
independent scientist he has made countless
contributions to many areas of research,
ranging from virology and telomere biology
to kidney cancer and population genetics.
What switched you on to a career in re-
search?
I was not a bright student, and I didn’t know
what I wanted to do. After secondary
school, I struggled into a 4-year course in
Medical Microbiology at Liverpool
University, but I wasn’t focussed – I enjoyed
sport and socialising, mainly. Rather than
decide what I wanted to study, I always did
the same courses as a friend of mine who
had been my roommate. In the last year of
our course he told me about a PhD post in
Cambridge on influenza virus replication.
So, we both applied, but only I was invited
for an interview and, remarkably, I got the
position.
So, I went to Cambridge. For the first
year and a half, I was over-awed. I felt I was
stupid and completely lacking in intellec-
tual confidence. And I really struggled at
the bench. For instance, I wanted to sepa-
rate influenza virus RNAs, but I couldn’t
even get my gels to set for a year. Finally, I
managed to produce some good data, and
it was this work that showed for the first
time that influenza virus replicated in the
nucleus, and that it used the host machin-
ery to produce its viral mRNAs and so on.
This was halfway through my PhD, and I
realised that I had produced something
useful – and that I wasn’t that stupid. I
gained some intellectual confidence, did
more experiments that worked and really
started to get the bug.
So, I decided I wanted to do a postdoc.
Having worked on the nucleus, I decided
that I was more interested in the host cell
than viruses, and I applied to do a postdoc
with someone who’s been one of the most
influential people in my scientific life. His
name was John Bishop. He was a very clever
and scary man, a big hotshot at the time,
and he was based in Edinburgh. He was
working on DNA reassociation kinetics –
which basically tells you something about
the complexity of nucleic acid molecules.
John had applied these approaches to study
the complexity of RNA molecules in cell
lines, and he’d published a Nature article on
this (Bishop et al., 1974). When I went to
work with him, I decided I wanted to study
this in real tissues. I looked at mouse brain,
liver and kidney, worked out the complex-
ity of the RNAs in each tissue, and deter-
mined the extent of overlap of specific sets
of RNAs in the different tissues. This was
eventually published in a Cell paper (Hastie
and Bishop, 1976), but not until 6 months
after I had completed my postdoc and gone
to work in the States.
What led you to take a job in the States?
I’ve hardly ever applied for a job in my life,
and my position in the States was no ex-
ception. RNA complexity was a hot topic at
that time, and someone from Roswell Park
Memorial Institute [now called Roswell
Park Cancer Institute] in Buffalo, New York,
wrote to John Bishop and asked him
whether he knew anyone with skills in that
area that they might be able to recruit. I had
never heard of the Institute, but I went and
did the interview. Apparently I gave a ter-
rible seminar, but the discussions after-
wards were good, and they offered me the
job, which meant I became a group leader
in the States at age 28.
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For 7 years in the states, I followed on
from work I’d done during my postdoc,
looking at liver gene expression during de-
velopment, identifying new genes in the
liver and looking at genome organisation in
the mouse. I had two NIH grants and a
lovely lab: two postdocs, three students and
two technicians. After a while, though, my
wife and I began to wonder whether we
should come back to the UK – parents were
growing older and all that. In 1982, Ed
Southern (of the famous Southern blot)
phoned to tell me that there was a position
available as a group leader at this MRC unit
[the Director at the time was Professor John
Evans, another major influence in my life].
The unit was very famous for its work on
chromosomes, but they were mainly using
microscopy and other descriptive tech-
niques, and they wanted someone that
would move them into the molecular realm.
I couldn’t do any lab work, really, so I was
very lucky to have some great people come
with me from the States – my then-
postdoc, Bob Hill, who is now a professor
and group leader here at the Human
Genetics Unit, and also Richard Meehan,
who was at that time a technician and is
now also a professor and group leader here.
This move coincided with a shift in your
research focus. What encouraged that?
On returning to Edinburgh, I decided that
I wanted to get away from mouse gene ex-
pression. I had to work on a human
problem, and I wanted to work on some-
thing that was really interesting biologically.
Veronica van Heyningen and I were
seduced by deletions on chromosome 11 in
patients with a childhood kidney cancer
called Wilms’ tumour. Children with these
deletions also have gonad problems, blind-
ness or aniridia [absence of the iris]. We
wanted to use this discovery as a way to find
genes that were key for human develop-
ment. I got very interested in this area, and
I’ll tell you why in a minute.
At the same time as I was getting into this
area, I was working on other aspects of
human chromosomes. For instance, Robin
Allshire, who was then at the MRC
Mammalian Genome Unit here in
Edinburgh, came to me with another
project. Robin put fission yeast chromo-
somes into mammalian cells to see if they
would replicate – and they did. We used
that system to identify human telomeres for
the first time. We got it slightly wrong, but
we did get there first, and that was pub-
lished in a Nature paper (Allshire et al.,
1988). Leading on from that, we studied
telomere dynamics and showed in real
tissues that telomeres shorten with every
year of life – that was also a Nature paper
and is by far my most cited paper (Hastie et
al., 1990).
Telomere biology was a hot area, but my
heart wasn’t really in it – I was most inter-
ested in Wilms’ tumour and the WT1 gene.
Why? Well, these tumours develop in chil-
dren within the first years of life, and the
disease is one of the best examples where
tumours arise because development has
gone awry. Also, inherited mutations in this
gene cause not only Wilms’ tumour, but
severe kidney problems, and sometimes
also heart problems or sex reversal. We
decided that this had to be a fascinating
gene that would tell us about disease as well
as normal development. Studying it led us
to find many interesting things, including
the identification of the Pax6 gene, which is
essential for eye development. We didn’t
identify the Wilms’ tumour gene [WT1] –
we were just beaten to the chase on that one
– but I’ve done a lot of work on it since. 
In fact, I’ve worked on this damn thing for
20 years! However, it’s the last 4 years that
have got me really excited. That’s because
we’ve started to really get at the mechanisms
by which these patients get tumours, kidney
problems, gonad problems, heart problems
and so on. Before recently, I’d never pub-
lished a mechanistic paper in my life – I’d
always worked on quite descriptive studies.
It’s my recent postdocs (Ofelia Martinez-
Estrada, Abdel Essafi and You-Ying Chau)
that have really dragged me into looking at
mechanisms. My postdocs, and sometimes
my students, are often the ones that dictate
what I do – I’m a cheerleader, really. I have
a few ideas, but they have a lot more.
What does WT1 do?
We’ve been making some progress recently
on the mechanisms by which WT1 acts, and
it’s looking more interesting all the time.
Basically, it looks like WT1 is a tumour
 suppressor during development, but in the
adult, it acts like an oncogene. How does the
absence of WT1 cause kidney and heart
problems in children? Briefly, our data show
that WT1 is essential during development
for the mesenchymal-to-epithelial transition
that gives rise to the epithelial cells of the
nephron. When WT1 is non-functional, this
transition doesn’t happen, and mesenchy-
mal tumours occur. In the heart, however,
the protein does something quite different.
Here, it’s required for an epithelial-to-mes-
enchymal transition that gives rise to heart
progenitor cells. Some of this is described 
in our recent Nature Genetics paper
(Martínez-Estrada et al., 2010). What’s
more, we’ve found that the genes activated
by WT1 in the kidney are repressed by WT1
in the heart, and vice versa. This is partly de-
scribed in a Developmental Cell paper from
last year (Essafi et al., 2011). In the same
study, we discovered that WT1 can recipro-
cally activate or repress a specific region of
chromatin to set up either an epithelial or
mesenchyme state. We call this feature ‘flip-
flop’.
So, that helps to explain what happens
during development when WT1 is deleted.
In the adult, however, WT1 is expressed at
high levels in many cancers, including
ovarian, breast, bowel and pancreatic, but
not in the normal epithelia from which
those cancers are derived. What’s its role
there? Well, this part of our work is exciting
me a great deal at the moment – part of the
story we just published in PLoS Genetics in
December (Chau et al., 2011). There’s a
theory out there that an epithelial-to-mes-
enchymal transition might be involved in
the production of stem cells in a number of
compartments, so we wanted to test
whether WT1 might have a role there. We
wanted to delete this gene in adult mice,
and look at the tissues that are normally af-
fected by cancer when the gene is mutated
– we wanted to test whether the stem cells
in those tissues were abnormal. So, we
knocked out Wt1 ubiquitously in 10-week-
old mature mice using a tamoxifen-Cre
system and, within 10 days, the mice died.
The kidneys failed, all body fat was lost, the
bone became completely osteoporotic, the
mice stopped making red blood cells and
the exocrine pancreas was 80% lost through
apoptosis. All of this happens within 5-8
days of knocking out the gene, and it
happens at least in part because deleting
Wt1 disrupts the haematopoietic and mes-
enchymal stem cell lineages. We don’t com-
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pletely know how this works yet, but these
are very dramatic phenotypes affecting
adult tissues in a matter of a few days, and
it’s really got me excited. I think we’re going
to learn new things about human disease,
stem cells, tissue homeostasis and tissue
repair through studying this.
You’re also involved in large-scale genetic
studies. What do you think has been the
most exciting development in this area
recently?
In a way, being able to do these huge GWAS
has been the most exciting recent develop-
ment. These studies have told us about the
genetic architecture of human traits, and
revealed how very complex the genetics of
disease susceptibility and complex traits
really are. They have told us about new
pathways and taught us about pathways we
thought we’d already figured out. Paper by
paper, these studies are very laborious, of
course, because there are so many traits to
examine and they just involve piles of data.
So, it’s essential to go the functional 
dimension.
In some projects I’m involved with,
we’re working on isolated populations in
Croatia and in Orkney. We do that because
we think the genetic structure is simpler
and the environment is less variable. There
is also more inbreeding, which might allow
us to get at recessive genes. It’s proved ex-
tremely successful. And we don’t just want
to map a gene of interest, we want to look
at function. For example, we mapped a
gene that regulates the levels of uric acid in
the blood (uric acid is vital for developing
gout). In people with high levels of uric
acid we found a gene that was reported to
encode a fructose transporter. When we
looked at it more carefully, we found that
it is an extremely efficient urate trans-
porter (Vitart et al., 2008). So, the genetics
led us to find a function for this gene that
was different from that which had initially
been described. We also showed that 
variation with this gene was associated
with susceptibility to gout, which is an 
increasing problem.
Something exciting that’s happened in this
unit is the development of a paradigm to
explain how very long-distance elements
regulate gene expression – these studies are
mainly led by Bob Hill, Veronica van
Heyningen and David Fitzpatrick. This is im-
portant because, when we do GWAS, half of
the things we map are in gene deserts, not
in genes. That means that a lot of the things
that dictate complex human traits are going
to be very long-distance chromosome
effects. That, to us, is one of the most excit-
ing developments: suggested roles for gene
deserts, regulatory elements and chromoso-
mal structure. What we’re trying to do here
in this unit is put this all together – to
combine complex human genetics and chro-
mosome biology to understand not only
traits and disease, but also more about the
regulation of gene expression.
There are a lot of big projects underway
that use whole-exome sequencing. If so
much is determined by variation in non-
coding regions, won’t this approach miss
some crucial things?
That’s true. But the aim of whole-exome se-
quencing is to find rare variants with large
effect. The larger effect variants will likely
affect proteins, whereas regions in gene
deserts or regulatory elements are more
likely to have small effects on a trait or a
disease – they likely contribute, but won’t
be where the gold is, so to speak. So, we
think the place to start, anyway, is exome 
sequencing.
If you could start over, what research
question or what disease would you
address?
If I were brave and could start again, it
would be to try to get at the basis of the
genetic factors involved in behavioural, psy-
chotic and related diseases. I would work on
bipolar disorder, schizophrenia, autism –
behavioural and cognitive defects like that.
To understand how the brain works is one
of the most challenging areas of research,
and studying the diseases that affect brain
function may provide major insights. The
hope would be to try to link genetics to the
biology of the brain – I think that would be
incredible.
My interest in this area is also personal.
Five years ago, my brother had a terrible
time with head and neck cancer, and he
died eventually. I was OK for about a year
after that, but then I became completely
neurotic about my health. I fell into a state
of major anxiety, and then depression, for
3 or 4 months. I couldn’t sleep, I lost all con-
fidence, and I thought I’d never done any-
thing valuable for anybody in science or in
my life. This was completely unlike me. But
I was lucky – I recovered, just in time for my
daughter’s wedding. But I’ll never forget
what it was like, how I couldn’t focus on
anything, how I lost all of my personality. I
got a glimpse into what these problems are
like for patients – some people suffer their
whole lives from these types of conditions,
and they are worse than a physical illness in
many ways.
But this area – it’s still a Cinderella thing.
There’s very little money going into mental
health research compared with funding for
diseases such as cancer and heart disease.
Huge amounts of money are needed to take
large cohorts of people with various cogni-
tive, behavioural and psychotic problems
and do sequencing and all the rest, and then
bring that together with biology. For
example, we are about to apply exome se-
quencing on a defined population of 24,000
Scottish people to find variants associated
with depression or cognitive variation.
What can you tell us that our readers
would be surprised to know about you?
Well, one thing that not many people know
about me is that I once considered a career
in singing, as a bass baritone. When I was in
Cambridge, I was offered a place in the
famous King’s College Choir. I decided not
to go that route, but I did continue to sing
solos over the years. Another thing you
might not guess is that I go to the gym four
or five times a week – I love Body Combat
and Body Pump and all of those sorts of
things. I think exercise is so important, and
I only started up again 5 years ago after
many years of not exercising – it’s some-
thing everyone should remember.
I would like to close by thanking all of the
wonderful people who have worked with
me over the years, including technicians,
postdocs, students and my long-suffering
PA, Katie Browne, and her assistant, Brenda
Henderson.
DMM greatly appreciates Nick Hastie’s
willingness to share his unique thoughts and
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experiences. He was interviewed by Sarah
Allan, Scientific Editor for DMM. This piece
has been edited and condensed with ap-
proval from the interviewee.Excerpts from
this interview can be heard in the podcast
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